Nurix Therapeutics is a clinical stage biopharmaceutical ... Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein ...

In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $35.00. Jeet Mukherjee has given his Buy ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Nurix Therapeutics is a clinical stage biopharmaceutical company ... Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), ...

SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

Nurix Therapeutics, Inc. (Nasdaq ... Strengthened balance sheet to support development of pipeline: Nurix ended its fiscal year with an estimated, unaudited $609.6 million in cash and investments ...